These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 8863597)

  • 1. Tuberculous iliac lymphadenitis: a rare complication of intravesical bacillus Calmette-Guerin and cause of tumor over staging.
    Ali-el Dein B; Nabeeh A
    J Urol; 1996 Nov; 156(5):1766-7. PubMed ID: 8863597
    [No Abstract]   [Full Text] [Related]  

  • 2. Mediastinal granulomatous lymphadenitis after intravesical bacillus Calmette-Guerin treatment mimicking distant metastasis of primary bladder carcinoma.
    Dogan D; Zor M; Ozkisa T; Ayten O; Yigit N; Yavas I
    Arch Bronconeumol; 2015 Oct; 51(10):526-7. PubMed ID: 25800325
    [No Abstract]   [Full Text] [Related]  

  • 3. [Severely contracted bladder following intravesical bacillus Calmette-Guérin therapy].
    Yoshimura K; Saiki S; Kuroda M; Kiyohara H; Kotake T
    Nihon Hinyokika Gakkai Zasshi; 1988 Nov; 79(11):1848-51. PubMed ID: 3216568
    [No Abstract]   [Full Text] [Related]  

  • 4. Tubercular prostatic abscess as a complication of intravesical bacillus Calmette-Guérin immunotherapy.
    Aust TR; Massey JA
    Int J Urol; 2005 Oct; 12(10):920-1. PubMed ID: 16323989
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A randomized prospective comparison of oral versus intravesical and percutaneous bacillus Calmette-Guerin for superficial bladder cancer.
    Lamm DL; DeHaven JI; Shriver J; Crispen R; Grau D; Sarosdy MF
    J Urol; 1990 Jul; 144(1):65-7. PubMed ID: 2193172
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prospective randomized comparison of intravesical with percutaneous bacillus Calmette-Guerin versus intravesical bacillus Calmette-Guerin in superficial bladder cancer.
    Lamm DL; DeHaven JI; Shriver J; Sarosdy MF
    J Urol; 1991 Apr; 145(4):738-40. PubMed ID: 2005691
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bacillus Calmette-Guerin versus doxorubicin versus thiotepa: a randomized prospective study in 202 patients with superficial bladder cancer.
    Martínez-Piñeiro JA; Jiménez León J; Martínez-Piñeiro L; Fiter L; Mosteiro JA; Navarro J; García Matres MJ; Cárcamo P
    J Urol; 1990 Mar; 143(3):502-6. PubMed ID: 2106041
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The expression level of ligands for natural killer cell receptors predicts response to bacillus Calmette-Guerin therapy: a pilot study.
    Yutkin V; Pode D; Pikarsky E; Mandelboim O
    J Urol; 2007 Dec; 178(6):2660-4. PubMed ID: 17945285
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A report of iliac muscle abscess due to Mycobacterium bovis after bacillus Calmette-Guerin therapy for bladder cancer.
    Talluri SK; Marigowda L; Besur S; Talluri J; Forstall GJ
    South Med J; 2010 Apr; 103(4):369-70. PubMed ID: 20224496
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Miliary tuberculosis secondary to transurethral bacillus Calmette-Guérin administration for superficial transitional cell carcinoma of the bladder.
    Skoutelis A; Melekos MD; Bassaris HJ
    J Natl Cancer Inst; 1990 Jul; 82(14):1219-20. PubMed ID: 2362292
    [No Abstract]   [Full Text] [Related]  

  • 11. Fatal disseminated mycobacterial infection following intravesical bacillus Calmette-Guerin.
    Deresiewicz RL; Stone RM; Aster JC
    J Urol; 1990 Dec; 144(6):1331-3; discussion 1333-4. PubMed ID: 2231918
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reactive arthritis following BCG immunotherapy for bladder carcinoma.
    Tinazzi E; Ficarra V; Simeoni S; Peterlana D; Lunardi C
    Clin Rheumatol; 2005 Aug; 24(4):425-7. PubMed ID: 15660288
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Granulomatous hepatitis following intravesical bacillus Calmette-Guerin therapy for bladder carcinoma.
    Marans HY; Bekirov HM
    J Urol; 1987 Jan; 137(1):111-2. PubMed ID: 3795348
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bacillus Calmette-Guerin in the treatment of stage T1 grade 3 transitional cell carcinoma of the bladder: long-term results.
    Pansadoro V; Emiliozzi P; Defidio L; Donadio D; Florio A; Maurelli S; Lauretti S; Sternberg CN
    J Urol; 1995 Dec; 154(6):2054-8. PubMed ID: 7500457
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Persistent acid-fast bacilli following intravesical bacillus Calmette-Guerin.
    Linn R; Klimberg IW; Wajsman Z
    J Urol; 1989 May; 141(5):1197-8. PubMed ID: 2709508
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A six-week course of bacillus Calmette-Guérin prophylaxis is insufficient to prevent tumor recurrence in nonmuscle invasive bladder cancer with strong-positive expression of p53.
    Oh JJ; Ji SH; Choi DK; Gong IH; Kim TH; Park DS
    Oncology; 2010; 79(5-6):440-6. PubMed ID: 21487231
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bacillus Calmette-Guerins vaccination at birth causing tuberculous granulomatous lymphadenitis.
    Al-Hassan AA; Ahsanullah AM
    Saudi Med J; 2011 Apr; 32(4):412-4. PubMed ID: 21484003
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reiter's syndrome postintravesical Bacillus Calmette-Guérin instillations.
    Ng KL; Chua CB
    Asian J Surg; 2017 Apr; 40(2):163-165. PubMed ID: 25183290
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Clinical experience with BCG immune prevention in superficial bladder cancer].
    Bach D; Romics I; Rüssel C
    Urologe A; 1992 Sep; 31(5):296-301. PubMed ID: 1302409
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of Adjuvant Intravesical Bacillus Calmette-Guérin Treatment on Patients with High-Grade T1 Bladder Cancer.
    Novotny V; Froehner M; Ollig J; Koch R; Zastrow S; Wirth MP
    Urol Int; 2016; 96(2):136-41. PubMed ID: 26789626
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.